Close Menu

cytogenetics

Things are looking up for CombiMatrix. The Irvine, Calif.-based molecular diagnostics firm this week reported preliminary revenue growth of 172 percent and 171 percent for billable prenatal tests in the fourth quarter of 2012 and full year 2012, respectively.

The global adoption of microarrays for the detection of genetic abnormalities has continued into the new year, with Chinese life sciences company CapitalBio announcing recently the introduction of chromosomal microarray analysis services via its medical testing laboratories.

This article was originally posted on Dec. 6.
Several studies published last week in the New England Journal of Medicine underscore the rapidly shifting landscape for genomic tools in the diagnostic setting.

"Explosive" and "enormous" are the words Simon Sheng uses to describe the market for microarray technology in China. As general manager for Affymetrix's office in the country, Sheng said he has hired eight sales and marketing personnel this year and hopes to add more soon.

Yongguo Yu is what the Chinese refer to as a "sea turtle," a professional who has received his education or pursued a career abroad, only to put any skills acquired to use upon return to his native country.

NEW YORK (GenomeWeb News) – Oxford Gene Technology announced on Tuesday the opening of an office in Tarrytown, NY, to support and grow its US business.

This story was originally posted on Oct. 24

The International Standards for Cytogenomic Arrays consortium has changed its name to reflect new collaborations with laboratories that rely mainly on next-generation sequencing, as well as with clinical geneticists for whom data interpretation and counseling, rather than technol

This article has been updated with comments from company officials.
NEW YORK (GenomeWeb News) – Illumina today announced that it has acquired Cambridge, UK-based BlueGnome for an undisclosed sum.

CGH+SNP or just SNP? Geneticists who use microarrays for constitutional and cancer cytogenetics have never had so many choices.

Pages

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.